Showing results (21-30 of 38) with videos related to
Sort By:
Pageof 4
Journal of Global Antimicrobial Resistance|July 15, 2023
Long-acting combination of cabotegravir plus rilpivirine: A picture of potential eligible and ineligible HIV-positive individuals from the Italian ARCA cohortAdriana Cervo, Antonio Russo, Domenico Di Carlo, et al.Journal of Global Antimicrobial Resistance|July 23, 2019
Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitorsRossana Scutari, Claudia Alteri, Ilaria Vicenti, et al.AIDS Research and Human Retroviruses|June 22, 2023
Factors Associated with Low-Level Viremia in People Living with HIV in the Italian Antiviral Response Cohort Analysis Cohort: A Case-Control StudyFrancesca Lombardi, Elena Bruzzesi, Yagai Romeo Bouba, et al.The Journal of Infectious Diseases|February 25, 2016
Multiple Hepatitis B Virus (HBV) Quasispecies and Immune-Escape Mutations Are Present in HBV Surface Antigen and Reverse Transcriptase of Patients With Acute Hepatitis BMarianna Aragri, Claudia Alteri, Arianna Battisti, et al.Chemical Biology & Drug Design|August 14, 2018
New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T)Lydia Pouga, Maria Mercedes Santoro, Charlotte Charpentier, et al.Antiviral Therapy|September 23, 2017
Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practiceMaria Mercedes Santoro, Domenico Di Carlo, Daniele Armenia, et al.Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|May 9, 2018
Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatmentDaniele Armenia, Mauro Zaccarelli, Vanni Borghi, et al.Journal of Viral Hepatitis|April 12, 2019
A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infectionRomina Salpini, Arianna Battisti, Luna Colagrossi, et al.Plos One|August 26, 2014
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAARTDaniele Armenia, Cathia Soulie, Domenico Di Carlo, et al.The Journal of Antimicrobial Chemotherapy|October 13, 2019
Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: a multi-cohort studySara Modica, David Redi, Roberta Gagliardini, et al.Pageof 4